ANNALS O F CLINICAL AND LABORATORY SCIEN CE, Vol. 8, No. 4Copyright © 1978, Institute for Clinical Science
Radioimmunoassay for Serum Myoglobin
ERNEST C. ADAMS, Ph.D., KATHLEEN M. LAYMAN,and IVARS JAUNAKAIS
Ames Research Laboratory, Division o f Miles Laboratories, Inc.,
Elkhart, IN 46514
ABSTRACT
A column flow-through radioimmune assay for serum myoglobin has been developed. The assay uses antibodies to human or rhesus monkey myoglobin coupled to Sepharose by cyanogen brom ide activation and myoglobin labeled by the Chloramine-T method. The labeled myoglobin is stable over two to three half-lives. Serum myoglobin levels were elevated when serum was taken up to 12 hours after myocardial infarction and generally elevated up to 24 hours. A continued or repeated elevation of serum myoglobin probably indicates continued myocardial damage or new a ttacks. In the cases of myocardial infarction, levels up to 1340 ng per ml were found.
Introduction
Myoglobin is the oxygen binding pigment of muscle. It can be extracted from muscle with water. Myoglobin is readily released into the blood as a result of dam age to muscle tissue. Because of its small size and lack of binding to haptoglobin, it is rapidly removed from the blood by the kidney and excreted into the urine. Since myoglobin is similar to hemoglobin in many of its properties and identical in its behavior in peroxidase-like reactions, its distinction from hemoglobin may be difficult. T he m yoglobin con ten t of red muscle, such as skeletal and heart, has been reported to be 2.1 to 3.4 mg per gm wet weight. It is highest in muscle that carries out sustained work with a slow period. White muscle does not contain m yoglobin. M yoglobin from sk e le ta l
m uscle and heart are iden tica l, both chemically and immunologically.10 Thus, myoglobinemia is an indication of muscle damage and not of heart alone. Properly, the assay should be referred to as one for serum m yoglobin and not one for myocardial infarction.
Previous reports from this laboratory have been concerned with the determ ination o f m yoglobin in u rine .1 It was shown that im m unochem ical m ethods could be used to distinguish myoglobin from hemoglobin and that myoglobinuria was a diagnostic sign for myocardial infarction.1,12,13 It would be expected that myoglobinemia would also be a useful sign. Since myoglobin is rapidly excreted in the urine, the amount in the serum following muscle damage is less than that in urine. The methods for urine myoglobin requ ire sensitiv ities in the /¿g per ml
3300091-7370/78/0700-0330 $01.80 © Institute for Clinical Science, Inc.
RADIOIMMUNOASSAY FO R SERUM M YOGLOBIN 3 3 1
range while the serum methods require sen s itiv itie s in the nanogram range. Kagen has reported the use of a complement fixation m ethod for assay of serum myoglobin.11 Three groups8,15,16 have reported the determination of serum myoglobin by radioimmune assay methods. All three groups used an equilibrium with antibody, labeled antigen and unlabeled antigen, followed by some means of separation of free from bound antigen such as am m onium su lfa te p rec ip ita tio n , polyethylene glycol precipitation or double antibody precipitation. Recently a commercial assay kit* based on double antibody has been placed on the market. Previously this laboratory reported on radioimmune assay methods using fixed antibodies in a column flow-through format.5,7 This m ethod has been extended to serum myoglobin.
Principle
The crude myoglobin is purified for immunization, for labeling and for standards by electrophoresis on acrylamide gel. Gamma globulin from specific antisera to human or monkey myoglobin is coupled to cyanogen bromide activated Sepharose to give a fixed antibody. The antibody-Sepharose, m ixed w ith plain Sepharose, is used to make a chromatographic column. W hen a serum containing myoglobin is passed through the column, some of the sites of the antibody are occupied. The remaining sites are available for binding when the labeled myoglobin is poured through the column. This is a non-equilibrium saturation method.
Reagents
P r e p a r a t io n o f C r u d e M y o g l o b in
Myoglobin is isolated from human or rhesus monkey muscle according to the selective precipitation m ethod of Lugin-
buhl.14 Hemoglobin and proteins other than m yoglobin are p rec ip ita ted from extracts of muscle at pH 8 with 80 percent am m onium sulfate saturation. U nder these conditions, the myoglobin remains in solution. Myoglobin is precipitated at pH 7 with 100 percent ammonium sulfate saturation. The precipitate is collected on 0.45 micron filters.!
E l e c t r o p h o r e s i s a n d E l e c t r o e l u t i o n o f M y o g l o b in
The myoglobin is further purified by electrophoresis on acrylamide gel which removes album in and other serum protein contaminants.1 To obtain material for immunization, the portion of gel containing the myoglobin bands is electroeluted. Colored elu ted fractions are pooled and the absorbance in the Soret band region is measured. After the elution, the myoglobin is in the ferro form; at a concentration of one mg per ml, this has an absorbance of 5.8 at 422 nm. From this value and the volume of elute, the total amount of m yoglobin is calculated. T he elu te which contains buffer material as well as myoglobin is lyophilized. For immunization, the myoglobin can be either human or monkey.
F or m yoglob in for lab e lin g or for s tan d a rd s, on ly the da rkest e lec- trophoresced band is used. This m ust be from human myoglobin if an assay with maximum sensitivity is desired. A plug containing the dark band is cut from the gel and inserted into a hole cut out of a new 5 percent acrylamide gel and the myoglobin is electroeluted. The elute is concentrated approximately ten times in the 15 ml cell* using a UM-2 membrane. This usually gives a solution of myoglobin containing about 2.5 mg per ml. The concentration is calculated from the absorbance before concentration.
* Nuclear Medical Systems, Inc., Newport Beach, CA.
f M illipore* Amicon®.
3 3 2 ADAMS, LAYMAN AND JAUNAKAIS
I m m u n iz a t io n a n d P r o c e s s in g o f An t is e r a
For immunization, castrated male goats aged 12 to 16 months are used. For the initial injection, w eight of lyophilized antigen calculated to contain 45 fig of myoglobin is dissolved in 0.5 ml saline (0.85 percent) and 0.5 ml Freund’s complete adjuvantf added. The mixture is emulsified in the micro cup of an Om- nim ixer| until the mixture is thick (ice is held around the cup). The em ulsified m ixture is in jected into the four dew claws of the goat.
For th e bo o ste r in jec tio n s , the lyophilized antigen (containing 45 fig of myoglobin) is dissolved in 0.5 ml saline. Half of this solution is stored in the refrigerator for the second of the divided pair o f boosters. To the rem ainder is added 0.25 ml of Freund’s incomplete adjuvant. This is em ulsified in the Omnimixer. The emulsion is injected I.M. in four sites, one in each quarter of the goat. After waiting 48 hours, the rem ainder of the antigen stored in the refrigerator is made up and injected in the same way. The schedule for initial injection, booster injections, test bleedings and final b leeding is the same as in the earlier reference1 except that there is a waiting period between the second and third pair of boosters in order to allow the antibody titer to fall near zero.
The antisera are checked for titer and specificity by immunodiffusion (Ouchter- lony) as described.1 The media for immunodiffusion now being used in the authors’ laboratory is 1 percen t agarose (electrophoretic grade)§ and 3 percent polyethylene glycol 400011 in B-2 buffer,** pH 8.6, ionic strength 0.025. An agar cutter with a 4 mm diam eter center w ell and 3 mm diam eter outer wells and
I Difco. t Sorval.§ Nutritional Biochemicals. 1 Fisher.** Harleco.
the centers of the center w ell and outer wells separated by 8 mm has been found convenient, although other arrangements may be used. The antisera should give a good precipitin line against a myoglobin solution or a urine containing myoglobin at levels of 40 to 50 fig per ml and no line against human album in at levels of 1000, 100, and 10 fig per ml or against human serum, f t
P r e p a r a t io n o f A n t ib o d y — Se p h a r o s e
The isolation of gamma globulin from the antisera by ammonium sulfate precipitation is essentially the m ethod used by Campbell and Garvey.3 A final solution of two ml contains the gamma globulin which was originally in a 10 ml volume of antiserum.
Two ml of the gamma globulin solution are mixed with 10.2 ml of cold citrate buffer (0.2M, pH 6.5). Three grams of cyanogen brom ide activated Sepharose are m ixed w ith 20 m l cold 0.001N h y drochloric acid for ten minutes. The activated Sepharose is washed on a coarse sintered glass filter with 600 ml 0.001N hydrochloric acid for a period of five m inutes; the mixing and washing must be done within a total of 15 minutes. Imm ed ia te ly afte r w ashing , the ac tiv a ted Sepharose is placed in a tube, the gamma globulin solution immediately added and end-over-end mixing is carried out automatically overnight in the refrigerator.
t t Antisera to human myoglobin are supplied commercially by the Research Products Division of Miles Laboratories (Elkhart, IN), by Cappel Laboratories (Downingtown, PA), and by JCL Clinical Research Corp. (Knoxville, TN). Antisera from these sources give good precip itin lines on immunodiffusion and immunoelectrophoresis and are suitable for hemagglutination inhibition determination of urinary myoglobin. They may be adequate for the radioimmune assay, but this can only be decided by trial as their behavior in the other assays does not necessarily predict the suitability for radioimmune assay. Just as any antisera, they must be checked for binding to the antibody column and for displacement by the standards.
RADIOIMMUNOASSAY FO R SERUM MYOGLOBIN 3 3 3
The gamma globulin-Sepharose mixture is collected on a coarse sintered glass filter and washed with 100 ml cold 0.2M citrate until the filtered washing has an absorbance at 280 nm less than 0.2. The antibody-Sepharose is washed with 500 ml cold saline (0.85 percent) until the absorbance of the washings at 21.5 nm is less than 0.1. T he an tibody-S epharose is w ashed w ith a sm all am ount of cold saline con tain ing 0.1 p e rcen t sodium azide. The antibody-Sepharose is washed w ith saline (w ith 0.1 percen t sodium azide) and diluted to 25 ml with saline (containing 0.1 percent sodium azide). This is mixed and allowed to stand overnight in the refrigerator. The antibody- Sepharose is made up to 25 percent (v/v) w ith sa line c o n ta in in g 0.1 p e rc e n t sodium azide.
For dilution of the antibody-Sepharose, Sepharose-4B is made up to 25 percent (v/v) concentration with saline containing 0.1 percent sodium azide. For determ ination o f the d ilu tion factor, sm all batches of 1:5, 1:10, 1:20, 1:50 and 1:100 of the antibody-Sepharose in the plain Sepharose are prepared . Colum ns are prepared, as to be described, from the dilu tions and the b in d in g w ith labeled myoglobin is determ ined. The dilution that will bind approximately 30 percent of freshly labeled myoglobin is chosen. A large batch of this dilution is prepared and used for the assay columns.
P r e p a r a t io n o f An t ib o d y C o l u m n s
The polypropylene columns are prepared elsewhere for the authors, bu t the barrel from any 3 ml disposable plastic syringe may be used. The porous filter sheet* is cut with a cork "borer to give discs of the diam eter of the inside diameter of the column. The discs are soaked in1 percent Brij 35 solution, rinsed twice with water and air dried.
* Vyon®.
Leuer caps are placed tightly on the tips of the columns. Approximately 1 ml of saline (0.85 percent) is placed into each of the columns. With a glass tube, a disc* (smooth side up) is forced down through the saline into the bottom of the column. The diluted antibody-Sepharose is thoroughly mixed with a m agnetic stirrer. While the mixture is still being stirred, two ml are removed with a two ml p ipet and rapidly added to one of the columns. This is repeated for the other colum ns. S im u ltaneously colum ns from plain Sepharose are prepared for serum blanks. The packed bed volume of the columns is 0.5 ml. The columns are allowed to stand upright for several hours or overnight. A second disc* is forced, with the glass tube, down through the liquid in all columns until it is tightly against the packed Sepharose with no air or liquid space. The Leuer tips are removed and the columns allowed to drain. The columns are equilibrated with bicine buffer (0.2M, pH 8.5) by filling each twice with the buffer and allowing the buffer to run through. The columns are prepared in large numbers ahead of time and stored in the refrigerator.
P r e p a r a t io n o f 1251-La b e l e d M y o g l o b in
The radioiodination of myoglobin is a modification of Greenwood et al.® The io d in a tio n is pe rfo rm ed in a glass septum -sealed reaction vial. M icroliter syringes are used in reagent transfers and additions. The Na 1251 in sodium hydroxide solution is neutralized w ith sufficient 0.3M phosphate buffer (pH 7.0) and the desired am ount of radioactivity is added to the reaction vial. Five fig of m yoglobin per mCi of 1251 are added, fo llow ed by su ffic ien t 0.1M ph o sphate buffer (pH 7.0) to bring the myoglobin concentration to approximately 0.27 tig p e r fi\ of to ta l reac tion volum e. T w en ty /u,l o f fresh ly p rep a re d
334 ADAMS, LAYMAN AND JAUNAKAIS
chloram ide-T dissolved in 0.3M phosphate buffer (pH 7.0) are added to the reaction vial. The concentration of the chloramide-T is such that the final concentration in the reaction vial is approximately 0.25 fig per fil. After 30 seconds, the radioiodination is quenched by the addition of sodium metabisulfate in 0.3M phosphate buffer (pH 7.0).
The radioiodination m ixture is then purified on a 1.0 x 30 cm Biogel P 10 colum n which was previously eq u ilibrated with 0.1M, pH 8.1 tris-hydroxy- ethyl aminomethane buffer containing 3 percent bovine serum album in and 0.2 percent sodium azide. E lution from the column is performed with 0.1M, pH 8.1 tris-hydroxy-ethylam inom ethane buffer containing 0.2 percent bovine albumin. The protein fractions are subsequently purified on a 1.5 x 50 cm Biogel P 30 column by elution w ith the 0.2 percent bovine serum album in in tris buffer. The fractions that show optimum immunological activity are saved. The specific activity is determ ined by trichloracetic acid precipitation of a small am ount of the radioiodination mixture. The specific activity of the preparation was 76 /xCi per fig of myoglobin. By altering the ratios, preparations with lower specific activity can be obtained. Preparations with as low specific activity as 14 fi Ci per fig have been successfully used in the assay. For use, the labeled myoglobin is diluted in bicine buffer (0.2M, pH 8.5) so that 0.5 ml contains approxim ately 30,000 cts per min.
P r e p a r a t io n o f St a n d a r d s
For standards, the concentrate, containing 1.8 to 2.7 mg per ml, of the eluted material from the single band of myoglobin is used. The actual amount is determ ined from the Soret band extinction before concentration, as described under the Preparation. This is d iluted 0.01 ml w ith 1 ml norm al goat serum (non- immune) to give the working dilution.
The working dilution is d iluted 0.1 ml with 0.9 ml normal goat serum. This dilution is serially d iluted with equal volumes of normal goat serum through seven tubes to give the other standards. Thus, if the original myoglobin concentrate contained 2.525 mg per ml, the working dilution would contain 25 fig per ml, and the standards would contain, 2500, 1250, 625, 312, 156, 78, 39 and 19.5 ng per ml, respectively.
R a d io im m u n o a s s a y f o r Se r u m M y o g l o b in
The Leuer tips should be on the columns at this point. Sufficient antibody columns for the blank, the standards the unknowns and a plain Sepharose column for the serum blank are used. Into each column is placed 0.4 ml of bicine buffer (0.2M, pH 8.5). This may be done ahead of time if both Leuer tips and caps are placed on the columns.) Precisely 0.1 ml of normal goat serum, a standard or an unknown is added to the antibody columns. The antibody column to which the normal goat serum is added serves as the blank, i.e., there is no unlabeled antigen and this column will have the greatest binding.
For the serum blank, 0.1 ml of normal goat serum is ad d ed to the p lain Sepharose column; this will measure the binding of the label to Sepharose. The contents of the columns are mixed by tapping. The L euer tips are rem oved from the columns and the columns allowed to drain. Thirty m inutes after removal of the tips, the tips are replaced and 0.5 ml of the diluted labeled myoglobin is added to each column. The tips are again removed and the columns allowed to drain. Thirty m inutes later, the columns are washed by filling the columns twice with bicine buffer. The drain ends of the columns are w iped with a tissue and the tip caps are replaced. The columns are counted in a well counter. For statistical values, the columns should be
RADIOIMMUNOASSAY FO R SERUM M YOGLOBIN 335
counted long enough to give counts of 10,000, but reasonable accuracy is obtained with counts of one minute.
Calculation
The counts per m inute rem aining in the p lain Sepharose colum n (colum n blank) are subtracted from the counts remaining in each of the antibody columns. The net counts per minute rem aining in the standard columns and unknown columns are divided by the net counts remaining in the blank antibody column (that with no unlabeled myoglobin) and the results expressed as percentage of the latter. When the column blank is small, its value may be ignored without introducing much error.
The percentage values for the standards are p lo tted agaist the m yoglobin concentration in ng per ml on log-logit paper. An example of a standard curve is given in figure 1. The myoglobin concentration of the unknowns is read from the standard curve.
A more detailed experim ental procedure may be found elsew here.17
Results
An t i g e n L a b e l in g
In figure 2 is shown the distribution of molecular weights of the labeled material when chromatographed on Biogel P-30. The hum p at the front of the curve probably represents label bound to albumin, while the m ain peak is myoglobin. The m yoglobin was c a lcu la ted to have a specific activity of 76 and 60 microcuries per ju.g, respectively, for the two preparations. In figure 3 is shown an autoradiograph of the labeled myoglobin immuno- electrophoresced against an antiserum to human myoglobin and an antiserum to monkey myoglobin. In figure 4 is shown, by the small increase of small molecules over a period of more than two half-lives, the stability of the labeled myoglobin. The stability of the label was also shown by the fact that the binding of antibody decreased only in the same ratio as the activity over the same period. This stability is in contrast to the instability in the lite ra tu re8,16 for ch loram ine-T -labeled myoglobin.
F igure 1. Standard curve for radioim m une assay of myoglobin. The label bound in the presence of a standard is plotted as a percentage of the label bound in the absence of a standard against nanograms of myoglobin on log-logit paper.
90
_______ I_______ I__________I_______ I__________I_______ I_______ I_10 20 40 100 200 500 1000 2000
NANOGRAMS PER MILLILITER
336 ADAMS, LAYMAN AND JAUNAKAIS
VO LU M E
F ig u r e 2. Fractionation of I 125 myoglobin on Bio-Gel P-30. The solid line is for a preparation with a specific activity of 60 microcuries per microgram. The dotted line is for a preparation with a specific activity of 76 microcuries per microgram.
M yoglobin was also labeled by the B o lton -H un ter m ethod in our own laboratories and by another.* These preparations also bound to the antibody and could be used in a radioimmune assay,
New England Nuclear, Boston, MA.
but the m inimal detectab le level was greater and the sensitivity was less.
Se l e c t io n o f An t is e r u m a n d R a t io o f A n t ib o d y -Se p h a r o s e t o S e p h a r o s e
An antiserum is selected on its ability to bind the label and also on the competition of the unlabeled protein with the label for the binding sites. In table I, it is shown that when the antisera to human myoglobin 220, 111, and 129 are attached to Sepharose, the label is bound but unlabeled myoglobin competes poorly with the label in the case of 220.
In table II is shown the binding of the label to several ratios o f an tibody- Sepharose to Sepharose for one of the antisera used in the preparation of this paper. The ratio giving about 30 percent binding with freshly labeled myoglobin was chosen.
S p e c ie s C r o s s R e a c t io n s
The antisera to the two species of myoglobin, the label on the myoglobin of the two species, and the inhibition by unlabeled m yoglobin of the two species were studied in all the possible combinations. In figure 5 it is shown that when the antibody to monkey myoglobin bound labeled human myoglobin, human myoglobin and monkey myoglobin competed equally. When the antibody to human myoglobin bound labeled monkey myoglobin, human and monkey myoglobin competed equally. However, when the antibody to monkey m yoglobin bound lab e led m onkey m yoglobin , hum an myoglobin was a poorer competer than monkey myoglobin. W hen the antibody to
ANTI HUMAN MYOGLOBIN
LABELED MYOGLOBIN
ANTI MONKEY MYOGLOBIN
F ig u r e 3. Autoradiograph of 1 125 myoglobin. The labeled myoglobin was electrophoresced on agarose-poly-ethylene glycol and diffused against antisera to human myoglobin and monkey myoglobin.
RADIOIMMUNOASSAY F O R SERUM MYOGLOBIN 3 3 7
human myoglobin bound labeled human m yoglobin, m onkey m yoglobin was a poorer competer than human myoglobin. It was also found that horse heart myoglobin and sperm whale myoglobin did not compete for e ither the human or monkey m yoglob in lev e l in e ith e r system . Likewise, ne ither hum an nor m onkey m yoglobin com peted with whale myoglobin in a system using antibody to whale myoglobin and labeled whale myoglobin.
R e a c t io n T i m e s : O p t im a l Vs . P r a c t ic a l
The binding of labeled myoglobin to an antibody-Sepharose colum n increases with time up to 16 hours. The competition of un labeled myoglobin increases with time up to four hours. This would suggest that an optimal sensitivity would be obtained w ith four-hour exposure to the standards and unknowns followed by a 16-hour exposure to the labeled myoglobin. Since a half-hour exposure to the unlabeled myoglobin and a half-hour exposure to the lab e led m yoglobin gives adequate sensitivity, these times were chosen for practical reasons.
R e c o v e r y o f A d d e d M y o g l o b in
Myoglobin was added to serum to give calculated levels of 866, 458, 117 and 65 ng per ml. D uplicate assays for these levels were 840 and 788, 460 and 395,120 and 122,78 and 78 ngper ml, respectively.
Once the principles of the m ethod were established, sera from two patients with diagnosed myocardial infarction were assayed. The values ranged from 334 to 1340 ng per ml. The serum with a level of 1340 ng per ml when diluted 1:5 was assayed as 250 ng per ml.
Sera from 11 patients with heart disease other than myocardial infarction were assayed for myoglobin. Three patients had values that would be considered abnormal. These three patients had heart enlargem en t, congestive h ea rt fa ilu re ,
(ODD)
VOLUME IN MILLILITERS
F ig u r e 4. Stability of labeled myoglobin. The increase in small molecules after two to three half-lives is shown by passing the label compound through Bio-Gel P-30.
pulmonary congestion and pneum onia. There was no evidence of acute myocard ia l infarction, although the patients had infarction in the past. The other eight patients had values in the normal range.
S e r u m L e v e l s f o r N o r m a l Su b j e c t s a n d H o s p i t a l iz e d P a t ie n t s W it h o u t M y o c a r d ia l I n f a r c t io n
Sera taken at random from ten laboratory personnel were assayed for myoglobin. The mean value found was 26 ± 26 ng
TABLE I
Competition of Human Myoglobin with I125 Labeled Human Myoglobin for Binding
Sites of Antibody to Human Myoglobin
Antiserum
Ratio of Antibody- Sepharose to
Sepharoseng per ml
Human Myoglobin
Percentof
Blank
220 1:10 610 76.53129 1:4 625 36.82111 1:4 250 69.55
3 3 8 ADAMS, LAYMAN AND JAUNAKAIS
TABLE II
Binding of Label with Ratios of Antibody-Sepharose to Sepharose
RatioCounts per Minute Added to Column
Counts per Minute Remaining on Column After Two Washes
PercentLabel
Bound
1:20 35,670 21,030 601:50 26,120 9,210 351:100 34,280 8,050 25
per ml with a range of 0 to 69 ng per ml. The scatter is shown in figure 6. Ninety- six sera from patients diagnosed as not having myocardial infarction had a mean value of 32 ± 8 ng per ml with a range from0 to 99 nanograms per ml. The scatter for these sera is also shown in figure 6.
S e r u m M y o g l o b in L e v e l s f o r P a t ie n t s A d m it t e d f o r M y o c a r d ia l I n f a r c t io n o r t o R u l e O u t M y o c a r d ia l I n f a r c t io n
Sera from 45 patients who were adm itted to a coronary care unit for myocardial infarction or to rule out myocardial infarction were assayed for m yoglobin. The
scatter of the values for the myocardial infarction is shown in figure 6 along with the normals and hosp ita lized w ithout myocardial infarction. N ineteen of the 24 patients diagnosed as having myocardial infarction had at least one elevated serum myoglobin. For two of the five patients without elevated serum myoglobin, the serum enzymes (total CPK, SGOT, LDH) were not elevated, the urine myoglobin was negative and the ECG was questionable; however, the diagnosis was myocardial infarction.
For the other three patients without elevated serum myoglobin, it is likely that the critical sera were not available. Values as high as 1120 ng per ml were found with most being in the 300 to 500 ng per ml range. W hen the tim e of myocardial infarction could be established by an objective sign such as onset of chest pain, it was shown that the serum myoglobin level rose in the first six hours, peaked in about 12 hours and fell to normal w ithin 24 hours. In some cases the serum myoglobin level rem ained elevated, indicating continued damage to the heart. In other cases
50
40
54
3 -
ANTIBODY LABEL INH IB ITO R
(1) M O N KEY M O N KEY M O N K E Y
(2) M O N KEY M O N KEY H U M A N
(3) M O N K E Y H U M A N M O NKEY
14) M O N K E Y H U M A N H U M A N
(5) H U M A N H U M A N M O N KEY
|6) H U M A N H U M A N H U M A N
(7) H U M A N M O N KEY M O N KEY
(8| H U M A N M O N K E Y M O NKEY
F ig u r e 5. E ffec t of species used for immunogen, label and antigen.
RADIOIMMUNOASSAY FO R SERUM M YOGLOBIN 3 3 9
the level peaked, fell to normal and then later rose again, probably indicating a new attack. Sometimes, there were elevated levels of myoglobin in the serum drawn on admission. This suggested that the infarction had occurred some time earlier and was generally confirmed by the clinical history.
N ineteen of the 21 patients diagnosed as not having myocardial infarction had no elevated serum myoglobin level. Two of the 21 patients had at least one elevated myoglobin level. These two patients also had urinary myoglobin.
C o r r e l a t io n o f S e r u m a n d U r in a r y M y o g l o b in
For 15 of the patients with diagnosed myocardial infarction, it was judged that both serum and urine had been collected at the critical times. The sera was assayed by radioimmune assay and the urines by hemagglutination inhibition. Fourteen of the patients had myoglobin both in serum and urine. One had myoglobin in serum but not in the urine. The sensitivities of the two m ethods are d ifferen t, being about 20 to 40 ng per ml for the radio- immune assay and 0.5 to 1 /xg per ml for the hemagglutination inhibition.
Discussion
N o r m a l a n d A b n o r m a l L e v e l s
Jutzy et al8 reported that none of their subjects w ithout myocardial infarction had serum myoglobin levels higher than 88 ng per ml and that the lowest level from a myocardial infarction patient was 130 ng per ml. An arbitrary level of 100 ng per ml was chosen as the divider betw een normal and abnormal. Serum myoglobin elevation was reported as early as 30 minutes after the infarct. The highest values were found in the first 12 hours and the myoglobin largely disappeared from the serum w ithin 24 hours. These observations are in agreem ent with those of the present
SUBJECTS
F ig u r e 6 . M yoglobin levels for normals, hospitalized patients and patients with myocardial infarct. The solid lines give the means for the first two groups and the points are the values of individual sera for all groups.
authors concerning m yoglobinuria following myocardial infarction. Most of the values of Jutzy et a l8 were in the range of 200 to 500 ng per ml although one was 6000 ng per ml.
Stone et al16 reported that levels from normal subjects were all lower than 85 ng per ml, while the mean value when the se ra w ere d raw n from p a tie n ts w ith myocardial infarction w ithin 12 hours after admission was 380 ng per ml. Two of the 20 patients with myocardial infarction did not have myoglobin levels above the
340 ADAMS, LAYMAN AND JAUNAKAIS
Situations Associated with Myoglobinémie States
TABLE I I I
I. TRAUMA AND ISCHEMIC DISEASE Trauma-crush syndrome Arterial ischemia
Extremities Myocardial infarction Pressure necrosis-coma
Surgical procedures Cardiac Orthopedic Vascular
II. EXERTIONAL STATESExertion in otherwise normal individuals Convulsive disorders
III. METABOLIC FACTORSAlcoholic myopathy Anesthetic-associated
Syndromes-malignant Hyperthermia
Defects in carbohydrate metabolism McArdle's disease Phosphofructokinase deficiency Syndrome of abnormal glycosis Defect in lipid metabolism Hypokalemia and potassium depletion states Toxic factors
Heroin user's myoglobinuria Animal venoms Quail eater's disease Haff disease Miscellaneous
IV. MYOSITIS SYNDROMES Dermat ornyo s it i s PolymyositisSystemic lupus erythematosus
V. OTHER FACTORS Infection Tetanus Fever
VI. IDIOPATHIC MYOGLOBINURIAS AND FAMILIAL MYOPATHIES
normal. The chest pains in these two patients had occurred 40 and 23 hours before admission. In the present studies in a series of 10 normal subjects, the values ranged from 0 to 69 ng per ml with a mean value of 26 and a standard deviation of 26. No attempt was made to investigate the activities of the normal subjects. Based on this, the levels for the hospitalized patients as well as the other two studies, the adoption of the 100 ng per ml level by Jutzy et al8 as the dividing line seems reasonable. In our first study, in the case of the one patient with myocardial infarction for whom multiple sera were available, the values ranged from 334 to 1340 ng per ml. Sera from other patients with myocar
dial infarction ranged up to 1400 ng per ml.
Se n s it iv it y
The sensitivity or rather the minimal detectable level in the column m ethod as determ ined from the 90 percent level on the log-logit plot appears to be about 4 ng or 40 ng per ml. Jutzy et al8 claim a sensitivity of 1 ng per ml for their method. Stone et al16 claim they can detect as little as 0.5 ng myoglobin. Since 0.02 ml serum is being used in their assays, their claimed sensitivity is 25 ng per ml. The Nuclear Medical System Inc. claims for its kit a sensitivity of 0.5 ng or 5 ng per ml. Inspection of its standard curve would suggest a sensitivity or minimal detection level of 25 ng per ml.
In all cases, the sensitivities are defined from standards developed in the ind ividual laboratories and not by an outside reference laboratory. If the 100 ng per ml level is accepted as the dividing line, the claim ed extreme sensitivity of these other investigators is not required and the m inimal detectable level of 40 ng per ml for the column m ethod is acceptable. The column m ethod can cover the range up to and past 2500 ng per ml without dilution.
U t i l i t y
It would be expected that myoglobine- mia would be found in the conditions that result in myoglobinuria. These are listed in table III. Probably a major use of the radioimmunoassay for serum myoglobin would be for patients suspected of having myocardial infarction. With proper tim ing of the blood collection, it would be useful in confirming the diagnosis and possibly in estim ating the extent of myocardial damage. It should be emphasized, however, that the assay is one for serum myoglobin and that conditions o ther than myocardial infarction can result in elevation of the level.
RADIOIMMUNOASSAY FO R SERUM MYOGLOBIN 341
Values obtained for serial sera indicate that myoglobin is released into the serum in a few hours after myocardial infarction and then rapidly d isappears from the serum . C ontinuing elevation of serum m yoglobin probably means continuing myocardial damage while new peaks in levels indicate new attacks. The rise in serum myoglobin following myocardial infarction is at least as early as that of serum CPK, but myoglobin disappears from the serum earlier than CPK and the other enzymes. It is thus important to have the sera at the proper tim e for these studies.
References
1. Adams, E. C.: Differentiation of myoglobin and hemoglobin in biological fluids. Ann. Clin. Lab. Sci. 1 :208-221, 1971.
2. Adams, E. C. and E lliott , T. A.: Urinary myoglobin in myocardial infarction. J. Amer. Med. Assoc. 221:1013-1014, 1970.
3. Campbell, D. H., Garvey, J. S., Crem er , N.E., and Sussdorf , D. H .: Methods in Immunology. New York, W. A. Benjamin, Inc., 1963, pp. 118-120.
4. CUATRECASAS, P.: Protein purification by affinity chromatography. Derivations of agarose and polyacrylam ide beads. J. Biol. Chem. 245:3059-3065, 19707
5. D avis, J. W., Yoder , J. M., and Adams, E. C.: Rapid, column flow-through radioimmunoassay for insulin. Clin. Chim. Acta 66:379-386,1976.
6. G ree n w o o d , F. C., H unter , W. M., and G lover , J. S.: The preparation of I131-labeled
human growth hormone of high specific radioactivity. Biochem. J. 89:114-123, 1963.
7. J ohnson , P. K., Yod er , J. M., and Adams, E. C.: A rapid, flow-through radioimmunoassay for human chorionic somatomammotropin. Amer. J. Obst. Gyn. 225:45-50, 1976.
8. Jutzy , R. V., Nevatt, G. W., Palmer, F. J., and Nelson , J. C.: Radioimmunoassay of serum myoglobin in acute myocardial infarction. Amer. J. Cardiol. 35:147, 1975.
9. KaGEN, L. J.: Myoglobin. New York, Columbia University Press, 1973, p. 87.
10. KaGEN, L. J. and G u re v ic h , R.: Precipitin reactions of anti-human Myoglobin serum with several human and animal muscle extracts. Immunology 12:667-673, 1967.
11. Kagen, L. J., Sc h ed id t , S., and Roberts, L.: Myoglobinemia following acute myocardial infarction. Amer. J. Med. 58:177-182, 1975.
12. K e s s l e r , H. A., L i e b s o n , P. R., M a t - TENHEIMER, H., and ADAMS, E. C.: Acute myocardial infarction diagnosed by myoglobinuria. Arch. Intern. Med. i35:1181-1183,1975.
13. Levine , R. S., Alterm an , U., G ubner , R. S., and Adams, E. C.: Myoglobinuria in myocardial infarction. Amer. J. Med. Science 262:179-183, 1971.
14. LUGINBUHL, W. H.: Immunologic investigation of preparations of human myoglobin. Amer. J. Clin. Path. 38:487-493, 1962.
15. R o s a n a , T. G. and KENNY, M. A.: A radioimmunoassay for human serum myoglobin. Method development and normal values. Clin. Chem. 23:69-75, 1977.
16. St o n e , N. J., W il l e r s o n , J. T., G o m e z - Sanchez, C. E., and Waterman, M. R.: Radioimmunoassay of myoglobin in human serum. Results in patients with acute myocardial infarction. J. Clin. Invest. 56:1334-1339, 1975.
17. Sunderman, F. W.: Manual of Procedures for the Seminar on Proteins and Proteinopathies. Philadelphia, Institute for Clinical Science,1977, pp. 111-134.